Patient-derived stem cells model endometriosis in the lab

A patient’s genetic background can now travel into a controlled laboratory model of endometriosis. Scientists led by Julie Kim have developed a platform that turns induced pluripotent stem cells — iPSCs, cells reprogrammed from a patient — into endometrial stromal fibroblast-like cells, reproducing key molecular and hormonal features of the disease.

That matters because endometriosis has been difficult to study in human tissue. Researchers have faced limited access to samples, differences in where donors are in their menstrual cycle and the short lifespan of stromal cells, the connective-tissue cells involved in the uterine lining. The new cells retain the patient’s inherited genetic background, including risk factors associated with endometriosis.

In a study published in Science Advances, Hannah McDowell and colleagues compared gene activity in the iPSC-derived cells with previously published analyses of adult stromal cells from patients with endometriosis. The models shared a significant number of disease-associated pathways. They also differed in epigenetic pathways, which help regulate how genes work. Julie Kim said that pattern suggests chronic inflammation may leave lasting regulatory signals, alongside genetic susceptibility.

The practical consequence is a research system in which scientists can make disease-relevant cell types from individual patients and manipulate conditions in a controlled human context. The team is using the iPSCs to develop macrophages, specialized white blood cells, to study whether they intensify inflammation or fail to clear diseased tissue. It is also developing nociceptor sensory neurons to investigate why endometriosis can cause increased pain.

The platform is still a laboratory model. It may give researchers a clearer way to define disease mechanisms and evaluate future therapies, but it does not itself treat patients, and endometriosis remains a chronic disease with no cure.